News Home

Should You Buy SCYNEXIS Inc (SCYX) Stock on Wednesday?

Wednesday, December 22, 2021 10:30 AM | InvestorsObserver Analysts
Should You Buy SCYNEXIS Inc (SCYX) Stock on Wednesday?

The market has been high on SCYNEXIS Inc (SCYX) stock recently. SCYX gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bullish
SCYNEXIS Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on SCYX!

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With SCYX Stock Today?

SCYNEXIS Inc (SCYX) stock is lower by -8.81% while the S&P 500 is up 0.34% as of 10:29 AM on Wednesday, Dec 22. SCYX has fallen -$0.66 from the previous closing price of $7.49 on volume of 190,095 shares. Over the past year the S&P 500 has risen 26.25% while SCYX is up 10.16%. SCYX lost -$3.56 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for SCYNEXIS Inc click here.

More About SCYNEXIS Inc

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains. Click Here to get the full Stock Report for SCYNEXIS Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App